Studies indicate that high levels of TFR expression in many tumor types correlate with poor prognosis, and drugs targeting TFR1 may effectively disrupt the iron dependency of tumor cells, thereby inhibiting their growth (27, 137). This evidence concerns the gene TFRC and neoplasm.